As of June 30, 2026, Duality Biotherapeutics, Inc. carries a market capitalization of 16.41B, placing it among publicly traded companies globally. Its enterprise value stands at 13.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16.41B |
| Enterprise Value | 13.34B |
Duality Biotherapeutics, Inc.'s next confirmed earnings release is scheduled for March 23, 2027.
| Earnings Date | 3/23/2027 |
As of June 30, 2026, Duality Biotherapeutics, Inc. has 90.54M shares outstanding.
| Shares Outstanding | 90.54M |
These figures are as of June 30, 2026.
| PB Ratio | 9.79 |
| P/TBV Ratio | 9.81 |
As of June 30, 2026, Duality Biotherapeutics, Inc. maintains a current ratio of 1.99, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.99 |
| Quick Ratio | 1.74 |
| Debt / Equity | 26.16 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 231.00 |
As of the close on November 17, 2026, Duality Biotherapeutics, Inc.'s stock has declined approximately 72.83% over the past 52 weeks. The 50-day moving average sits at 158.22, while the 200-day moving average is 226.03.
| 52-Week Price Change | -72.83% |
| 50-Day Moving Average | 158.22 |
| 200-Day Moving Average | 226.03 |
As of June 30, 2026, Duality Biotherapeutics, Inc. holds 3.51B in cash and equivalents against 438.57M in total debt, resulting in a net debt position of -2.19B. Total book value stands at 1.68B, with working capital of 1.99B providing operational flexibility.
| Cash & Cash Equivalents | 3.51B |
| Total Debt | 438.57M |
| Net Debt | -2.19B |
| Equity (Book Value) | 1.68B |
| Book Value Per Share | 18.52 |
| Working Capital | 1.99B |
Already premium?